Poster Presentation 50th Lorne Proteins Conference 2025

Expanding the toolbox for targeted protein degradation (#406)

Michael J Roy 1 2 3 , Nicole Trainor 2 4 , Luke Duncan 2 4 , Andrew Tang 2 4 , Julia Beveridge 2 4 , Stephanie Nguyen 2 4 , Mona Radwan 2 4 , Nishma Gupta 2 4 , Peter Greb 5 , Sara Kopf 5 , Zuzana Jandova 5 , Krzysztof Zak 5 , Thomas Gerstberger 5 , Peggy Stolt-Bergner 5 , Federico Mauri 5 , Manfred Koegl 5 , Harald Weinstabl 5 , Peter Ettmayer 5 , Darryl B McConnell 5 , Nicola Chessum 5 , Isabelle Lucet 2 4 , John Silke 2 4
  1. Walter & Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
  2. Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
  3. Cancer Resistance Program, South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide, Adelaide, SA, Australia
  4. Walter & Eliza Hall Institute , Parkville, VIC, Australia
  5. Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
Publish consent withheld
  1. [1] Bekes, M., Langley, D. R., Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 2022, 21 (3), 181-200.
  2. [2] Roy, M. J. et. al. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. ACS Chem Biol 2019, 14 (3), 361-368.
  3. [3] Farnaby, W., Koegl, M., et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol 2019, 15 (7), 672-680.
  4. [4] Kofink, C., et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo, Nat Commun 2022, 13, 5969.
  5. [5] Krone, M.W and Crews, C.M. Next steps for targeted protein degradation, Cell Chem Biol 2024, DOI: 10.1016/j.chembiol.2024.10.004.
  6. [6] Silke, J. and Vince, J.; IAPs and Cell Death, In Apoptotic and Non-apoptotic Cell Death 2016, pp 95-117.